X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (127) 127
index medicus (116) 116
male (99) 99
female (95) 95
middle aged (86) 86
aged (78) 78
hematology (73) 73
life sciences (69) 69
adult (58) 58
rituximab (48) 48
treatment outcome (47) 47
aged, 80 and over (43) 43
oncology (43) 43
cancer (32) 32
chemotherapy (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
prognosis (29) 29
lymphomas (24) 24
cyclophosphamide (23) 23
retrospective studies (23) 23
therapy (23) 23
lymphoma (22) 22
time factors (22) 22
risk factors (21) 21
non-hodgkins-lymphoma (20) 20
survival (20) 20
human health and pathology (19) 19
surgery (19) 19
care and treatment (18) 18
hemic and lymphatic diseases (18) 18
lymphoma, follicular - drug therapy (18) 18
trial (18) 18
analysis (17) 17
disease-free survival (17) 17
follow-up studies (17) 17
peripheral vascular disease (17) 17
research (17) 17
[ sdv ] life sciences [q-bio] (16) 16
abridged index medicus (16) 16
leukemia, lymphocytic, chronic, b-cell - drug therapy (16) 16
prospective studies (16) 16
follicular lymphoma (15) 15
patients (15) 15
survival analysis (15) 15
young adult (15) 15
[sdv.can]life sciences [q-bio]/cancer (14) 14
[sdv]life sciences [q-bio] (14) 14
antineoplastic agents - therapeutic use (14) 14
diagnosis (14) 14
mortality (14) 14
[ sdv.can ] life sciences [q-bio]/cancer (13) 13
adolescent (13) 13
antibodies, monoclonal, murine-derived - therapeutic use (13) 13
b-cell lymphoma (13) 13
cyclophosphamide - administration & dosage (13) 13
doxorubicin (13) 13
france (13) 13
prednisone (13) 13
transplantation (13) 13
vincristine (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
clinical trials (11) 11
cyclophosphamide - therapeutic use (11) 11
disease (11) 11
elderly-patients (11) 11
hematology, oncology and palliative medicine (11) 11
kaplan-meier estimate (11) 11
lymphoma, large b-cell, diffuse - drug therapy (11) 11
multivariate analysis (11) 11
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (10) 10
antibodies, monoclonal, murine-derived (10) 10
antibodies, monoclonal, murine-derived - administration & dosage (10) 10
immune system diseases (10) 10
open-label (10) 10
remission induction (10) 10
survival rate (10) 10
transplantation, autologous (10) 10
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (9) 9
chronic lymphocytic leukemia (9) 9
cll (9) 9
doxorubicin - administration & dosage (9) 9
elderly (9) 9
expression (9) 9
immunology (9) 9
lymphoma, follicular - pathology (9) 9
management (9) 9
medical prognosis (9) 9
minimal residual disease (9) 9
plus rituximab (9) 9
recurrence (9) 9
salvage therapy (9) 9
studies (9) 9
antibodies, monoclonal - administration & dosage (8) 8
autografts (8) 8
combined modality therapy (8) 8
cyclophosphamide - adverse effects (8) 8
genetic aspects (8) 8
health aspects (8) 8
hematopoietic stem cell transplantation (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Future Oncology, ISSN 1479-6694, 05/2015, Volume 11, Issue 9, pp. 1327 - 1342
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
SURVIVAL | FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | RITUXIMAB | COMBINATION | FLUDARABINE | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article